-
公开(公告)号：US10988533B2
公开(公告)日：2021-04-27
申请号：US15548871
申请日：2016-02-05
IPC分类号： A61K39/395 , C07K16/28 , A61P35/02
摘要： This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.
-
2.发明申请Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors 审中-公开用于选择性抑制ABCB1，ABCC1和ABCG2转运蛋白的化合物和方法以及治疗癌症，特别是耐药性癌症和高通量流式细胞术检测选择性抑制剂公开(公告)号：US20090208493A1
公开(公告)日：2009-08-20
申请号：US12315132
申请日：2008-11-28
申请人： Richard S. Larson , Larry A. Sklar , Bruce S. Edwards , Irena D. Ivnitski-Steele , Tudor I. Oprea , Debbie M. Lovato , Hadya M. Khawaja , Stuart S. Winter , Susan M. Young
发明人： Richard S. Larson , Larry A. Sklar , Bruce S. Edwards , Irena D. Ivnitski-Steele , Tudor I. Oprea , Debbie M. Lovato , Hadya M. Khawaja , Stuart S. Winter , Susan M. Young
CPC分类号： A61K31/12 , A61K31/415 , A61K45/06 , A61K2300/00
摘要： Compounds disclosed which inhibit ABCB1 transporter protein are useful for treating diseases in which ABCB1 transporter protein mediates the disease state, including numerous cancers, including hematopoietic cancers, including various leukemias, especially T-lineage acute lymphoblastic leukemia, as well as cancerous tumors, especially forms which exhibit multiple drug resistance. Pharmaceutical compositions which comprise an inhibitor of ABCB1 transporter protein and at least one additional anticancer agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient are another aspect of the present invention. A flow cytometry based, high-throughput screening (HST) assay that quantifies ABCB1 efflux is also disclosed. Methods of identifying inhibitors of ABCB1, ABCG2 and ABCC1 transporter proteins are also disclosed.
摘要翻译： 公开的抑制ABCB1转运蛋白的化合物可用于治疗其中ABCB1转运蛋白介导疾病状态的疾病，包括许多癌症，包括造血癌，包括各种白血病，特别是T-lineage急性成淋巴细胞白血病，以及癌性肿瘤，特别是形式 其表现出多种耐药性。 包含ABCB1转运蛋白抑制剂和至少一种另外的抗癌剂的药物组合物，任选与药学上可接受的载体，添加剂或赋形剂组合是本发明的另一方面。 还公开了量化ABCB1流出的基于流式细胞术的高通量筛选（HST）测定。 还公开了鉴定ABCB1，ABCG2和ABCC1转运蛋白抑制剂的方法。
-
公开(公告)号：US20180022805A1
公开(公告)日：2018-01-25
申请号：US15548871
申请日：2016-02-05
IPC分类号： C07K16/28
CPC分类号： C07K16/2803 , A61K39/3955 , C07K2317/21 , C07K2317/24 , C07K2317/35 , C07K2317/52 , C07K2317/55 , C07K2317/622 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： This disclosure describes the identification of pre-B Cell Receptor (pre-BCR) antagonists and the use of pre-BCR antagonists as a targeted therapy. The compositions and methods generally involve a composition that includes a pre-B cell receptor (pre-BCR) antagonist and is engineered for expression as a T cell chimeric receptor. In some embodiments, the pre-BCR antagonists can include an anti-pre-BCR antibody.
-
-
搜索结果
3 条记录 (耗时 0.017 秒)
